Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong Tu

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinomaLai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, et al.
Journal of Medicinal Chemistry|January 9, 2014
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymeraseRobert G Gentles, Min Ding, John A Bender, et al.
Journal of Medicinal Chemistry|February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.
Journal of Medicinal Chemistry|February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinomaLai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, et al.
Journal of Medicinal Chemistry|January 9, 2014
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymeraseRobert G Gentles, Min Ding, John A Bender, et al.
Journal of Medicinal Chemistry|February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.
Journal of Medicinal Chemistry|February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.
Pageof 7